Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $53.00 Average PT from Analysts

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have earned an average recommendation of “Hold” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $53.00.

CTXR has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, October 8th. D. Boral Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a report on Wednesday, August 13th. Finally, Wall Street Zen lowered shares of Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, September 26th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Arkadios Wealth Advisors raised its holdings in Citius Pharmaceuticals by 100.0% in the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock valued at $32,000 after buying an additional 10,000 shares during the period. XTX Topco Ltd purchased a new position in Citius Pharmaceuticals in the second quarter valued at approximately $32,000. Finally, NewEdge Advisors LLC purchased a new position in Citius Pharmaceuticals in the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $1.57 on Tuesday. Citius Pharmaceuticals has a 12-month low of $0.65 and a 12-month high of $12.84. The stock has a market capitalization of $26.71 million, a P/E ratio of -0.47 and a beta of 1.41. The firm’s 50-day moving average is $1.33 and its two-hundred day moving average is $1.22.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.04). The business had revenue of $1.92 million for the quarter, compared to the consensus estimate of $1.92 million. As a group, analysts forecast that Citius Pharmaceuticals will post -4.5 EPS for the current year.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.